InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer's Treatment

InMed Pharmaceuticals Inc. (NASDAQ: INM) has revealed new preclinical data indicating that its compound, INM-901, significantly reduces inflammation in models of neuroinflammation, a key factor in Alzheimer's disease progression. The findings show a dose-dependent reduction in pro-inflammatory cytokines and inflammasome markers, independent of amyloid beta or tau pathology, suggesting INM-901's broader applicability in treating neurodegenerative diseases. The compound, which targets CB1/CB2 receptors and PPARs, has also demonstrated improvements in cognition and behavior in long-term animal studies. InMed is preparing to advance INM-901 through further preclinical and IND-enabling studies, with Alzheimer's disease as the lead indication. For more details, visit https://ibn.fm/HBoFJ.